Belpointe Asset Management’s West Pharmaceutical WST Stock Holding History

Belpointe Asset Management’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,627	Closed	-$644K	–	946
2024 Q1	$644K	Buy	+1,627	New	+$602K	0.05%	378
2023 Q2	–	Sell	-1,862	Closed	-$645K	–	3393
2023 Q1	$645K	Buy	1,862 +1,584	+570%	+$463K	0.03%	460
2022 Q4	$65.5K	Buy	+278	New	+$65.9K	﹤0.01%	1465
2022 Q3	–	Sell	-1,504	Closed	-$454K	–	1241
2022 Q2	$454K	Buy	1,504 +355	+31%	+$116K	0.03%	528
2022 Q1	$472K	Buy	1,149 +894	+351%	+$350K	0.03%	556
2021 Q4	$119K	Buy	255 +13	+5%	+$5.6K	0.01%	1121
2021 Q3	$103K	Buy	+242	New	+$102K	0.01%	1153
2021 Q2	–	Sell	-2,464	Closed	-$694K	–	1187
2021 Q1	$694K	Buy	+2,464	New	+$705K	0.06%	329
2020 Q3	–	Sell	-2,295	Closed	-$522K	–	827
2020 Q2	$522K	Buy	+2,295	New	+$451K	0.07%	295

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Belpointe Asset Management's WST Position: Q2 2024 in Review

Belpointe Asset Management sold out of West Pharmaceutical (WST) in Q2 2024, closing a stake of 1,627 shares — an estimated $644K sold.

Belpointe Asset Management first reported a position in WST in Q2 2020 and held it in 9 quarters. The position peaked at $694K in Q1 2021. 777 funds tracked by Wall St. Rank hold WST as of Q2 2024.

Belpointe Asset Management reported no remaining West Pharmaceutical position as of Q2 2024 after selling out during the quarter.
Belpointe Asset Management sold 1,627 West Pharmaceutical shares in Q2 2024, an estimated $644K.
Belpointe Asset Management first reported a position in West Pharmaceutical in Q2 2020 and held it in 9 quarters.
Belpointe Asset Management's West Pharmaceutical position peaked at $694K in Q1 2021.
777 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2024.

Based on Belpointe Asset Management's 13F filing for Q2 2024, filed 2 Aug 2024.